Coagulation proteases and cardiovascular disease

Hugo ten Cate; Gordon Lowe

doi:10.1160/th14-09-0781

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2014; 112(05): 858-859
DOI: 10.1160/th14-09-0781

Theme Issue Editorial

Schattauer GmbH

Coagulation proteases and cardiovascular disease

Authors

Hugo ten Cate

¹Department of Internal medicine and Thrombosis Center, Maastricht University Medical Center and Cardiovascular Research Institute Maastricht (CARIM), Maastricht, the Netherlands

²Center for Thrombosis and Haemostasis, Gutenberg University, Mainz, Germany
Gordon Lowe

³Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland, UK

Abstract

Full Text

References

References
1 Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 1095: 1135-1143.
2 Lowe GDO. Can haematological tests predict cardiovascular risk? The 2005 Kettle Lecture. Br J Haematol 2006; 133: 232-250.
3 Borissoff JI, Spronk HMH, Cate Ten H. The haemostatic system as a modulator of atherosclerosis. N Engl J Med 2011; 364: 1746-1760.
4 Ruff CT, Giugliano RP, Braunwald E. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials. Lancet 2014; 383: 955-962.
5 Lowe GDO, Rumley A. The relevance of coagulation in cardiovascular disease: what do the biomarkers tell us?. Thromb Haemost 2014; 112: 860-867.
6 Bjorkqvist J, Nickel KF, Stavrou E. et al. In vivo activation and functions of the protease factor XII. Thromb Haemost 2014; 112: 868-875.
7 Rezaie A. Protease-activated receptor signalling by coagulation proteases in endothelial cells. Thromb Haemost 2014; 112: 876-882.
8 Mosnier LO, Zlokovic BV, Griffin JH. Cytoprotective-selective activated protein C therapy for ischaemic stroke. Thromb Haemost 2014; 112: 883-892.
9 Antoniak S, Sparkenbaugh E, Pawlinski R. Tissue factor, protease activated receptors and pathologic heart remodeling. Thromb Haemost 2014; 112: 893-900.
10 Bridge KI, Philippou H, Ariens RAS. Clot properties and cardiovascular disease. Thromb Haemost 2014; 112: 901-908.
11 Schurgers LJ, Spronk HMH. Differential effects of old and new oral anticoagulants: consequences to the genesis and progression of atherosclerosis. Thromb Haemost 2014; 112: 909-917.
12 Vanassche T, Hirsh J, Eikelboom JW, Ginsberg JS. Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials. Thromb Hae-most 2014; 112: 918-923.